Insulet beats quarterly estimates on strong demand for wearable insulin pumps | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]- Companies[Dexcom Inc]Follow[Insulet Corp]FollowFeb 18 (Reuters) - Insulet [(PODD.O), opens new tab] reported better-than-expected fourth-quarter results on Wednesday, on the back of strong demand for its tubeless insulin pumps that eliminate the need for daily injections.The medical device maker also forec ...

Core Insights - Institutional interest in medical device makers is increasing, supported by strong operating updates from industry leaders [1] - Hedge fund Armistice Capital is focusing on small- and mid-cap device companies, while BlackRock and State Street are investing heavily in larger manufacturers through sector funds [1][16] Group 1: Institutional Investments - Armistice Capital increased its position in NeuroPace by approximately 95% in Q1 2025, holding 1.15 million shares [2] - Armistice also disclosed a near-10% passive stake in Nevro, owning 3.736 million shares [3] - BlackRock's iShares U.S. Medical Devices ETF (IHI) has about $4.6 billion in net assets, with top holdings in major companies like Abbott Laboratories and Intuitive Surgical [4] - State Street's SPDR S&P Health Care Equipment ETF (XHE) manages roughly $155 million in assets, providing balanced exposure across the equipment segment [5] - Both BlackRock and State Street are significant shareholders in various medical device companies through their index and active products [6] Group 2: Industry Performance - Boston Scientific reported Q2 sales of $5.06 billion, a 23% increase year-over-year, and raised its full-year outlook [7] - Intuitive Surgical's Q2 revenue reached $2.44 billion, a 21% increase, driven by higher procedure volumes [8] - Insulet's Q2 revenue rose 32.9% to $649.1 million, supported by the adoption of its Omnipod insulin-delivery system [9] - Dexcom reported a 15% revenue growth to $1.157 billion for the quarter, updating its full-year guidance [9] - These strong updates validate ongoing demand for medical devices, particularly in cardiovascular interventions and diabetes technology [10] Group 3: Future Outlook - Armistice Capital is focused on clinical milestones and commercial execution at smaller companies like NeuroPace and Nevro [14] - BlackRock and State Street are monitoring whether the momentum in the device sector continues through year-end reporting cycles [15] - Upcoming updates from major players like Boston Scientific, Intuitive Surgical, Insulet, and Dexcom will be critical indicators of market strength [15]